Ironwood Pharmaceuticals to Host Second Quarter 2025 Investor Update Call
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
香港伟理服务器ip免费
Interested in Joining Our Team?
Copyright © 2025, Ironwood Pharmaceuticals, Inc. All Rights Reserved
LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.
This link will take you to a website to which our privacy policy does not apply. You are solely responsible for your interactions with that website.